US Drug Watchdog Now Urges Women Who are Transvaginal Mesh Victims to Call Them For the Names of the Best Women Attorneys-No Other Group Offers This Very Vital Service

October 9, 2012

The US Drug Watchdog is attempting to create a much better environment for women who are victims of a transvaginal mesh, or sling failure. The group is offering victims of a transvaginal mesh failure the names, and specific contacts for national caliber personal injury attorney who are all women. The US Drug Watchdog says, “We are 110% certain a victim of a transvaginal mesh, or sling failure will not want to talk specifics about their transvaginal mesh failure to a male attorney, so we have built a team of the best possible women attorneys in the country. We think our approach to transvaginal mesh failures is a game changer for any women who is a victim.” Transvaginal mesh failure occurs when the mesh fails to bind to a woman’s pelvic tissues. As a consequence of this, the body rejects the mesh that has been sewn into it. As a result, the transvaginal mesh may start to poke its way through the vaginal wall and protrude out of the vaginal tissue. The US Drug Watchdog is urging any woman, who has had the transvaginal mesh surgical procedure done, and now has developed severe complications to call them anytime at 866-714-6466 http://USDrugWatchdog.Com

(PRWEB) October 08, 2012

The US Drug Watchdog has launched a very aggressive national initiative focused on identifying all women recipients of a transvaginal mesh failure, who are now severely damaged by this type of product-with the promise-all of the attorneys they will suggest will be women. As a background transvaginal mesh products were designed for women, who were suffering from pelvic organ prolapse, and stress urinary incontinence. Initially the US FDA called the procedure to install a transvaginal mesh-minimally-invasive. According to court records, women who experience a transvaginal mesh failure may need to have numerous corrective surgeries, IV therapy, blood transfusions and drainage of hematomas or abscesses. The US Drug Watchdog is offering to help all US women, who are now victim’s of a transvaginal mesh failure get to the best possible attorneys, and again the group is promising the attorneys will all be women. The US Drug Watchdog believes making top notch women attorneys available to any victim of a transvaginal mesh, or sling failure is a vital service. For more information victims of a transvaginal mesh, or sling failure are urged to contact the US Drug Watchdog anytime at 866-714-6466. http://USDrugWatchdog.Com

The US Drug Watchdog is indicating symptoms of a transvaginal mesh implant failure may include:

  • Pain during sexual intercourse caused by erosion.
  • Mesh erosion through the vagina (the mesh is actually protruding out of the vaginal wall)
  • Vaginal Bleeding
  • Vaginal Infection
  • Urinary problems
  • Organ perforation

The US Drug Watchdog says, “One of the biggest problems we have with respect to our failed medical device or recalled drug initiative work is the average US consumer never hears about a drug recall or failures involving medical devices like the transvaginal mesh. If you have a friend, or loved one who is a recipient of a transvaginal mesh, or sling that has already failed or is showing symptoms of a failure, please have them call us at 866-714-6466. We want to make certain these transvaginal mesh victims get to the best possible attorneys, to ensure they get the best possible compensation for their ordeal, and we will do our absolute best to make certain all of the attorneys are women.” http://USDrugWatchdog.Com

U.S. District Court for the Southern District of West Virginia Multidistrict litigation (MDL) consolidates all similar cases into one courtroom and will include the Defendants:

C.R. Bard, Inc., (MDL No. 2187);

American Medical Systems Inc., MDL No. 2325);

Boston Scientific Corp., (MDL No. 2326); and Johnson & Johnson’s Ethicon, Inc. (MDL No. 2327)

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb9976027.htm

Source: prweb

comments powered by Disqus